Top news from ADA: Tirzepatide, cell therapy, glucokinase inhibition and more
Click Here to Manage Email Alerts
The Healio and Endocrine Today editors have compiled the most read news from the American Diabetes Association Scientific Sessions in June.
Readers were most interested in learning about strategies for treating obesity and type 2 diabetes, and therapies in development for treating — and perhaps curing — type 1 diabetes. Here are 5 of Healio’s most-read news stories from the meeting.
Weekly tirzepatide confers substantial weight loss in obesity without diabetes: SURMOUNT-1
Nearly all participants with obesity without diabetes assigned tirzepatide experienced at least 5% weight loss over 72 weeks compared with placebo, with at least 20% weight loss in more than half with the highest 15 mg dose.
First patient gains insulin independence with novel stem cell-derived islet cell therapy
A man with long-standing type 1 diabetes and no endogenous insulin production achieved insulin independence after an infusion of an investigational stem cell-derived pancreatic islet cell therapy, researchers reported.
Experts debate obesity vs. glycemic control as primary target for treating type 2 diabetes
Obesity should be a primary target for most with type 2 diabetes, but goals can vary based on an individual’s profile. Although not sufficient on its own, glycemic control should be another primary target.
‘Counterintuitive’ glucokinase inhibition may help prevent, reverse type 2 diabetes
A novel “counterintuitive” intervention that reduces glucokinase activity and limits the buildup of metabolites may enhance insulin secretion and ultimately prevent or even reverse type 2 diabetes.
Bionic pancreas reduces HbA1c, improves time in range in type 1 diabetes: Pivotal data
Adults and children with type 1 diabetes who used an insulin-only bionic pancreas had reduced HbA1c without increasing hypoglycemia and other improved metrics compared with standard of care.
Collapse
Healio coverage
Read more about
Click Here to Manage Email Alerts